ISSN: 1301-2193 E-ISSN: 1308-9846
  • Turkish Journal of
    Endocrinology and Metabolism
ORIGINAL ARTICLE

Symptomatic Hyperprolactinemia: A Six Years of Experience
Symptomatic Hyperprolactinemia: A Six Years of Experience
Makale Dili: EN
Bu makale, CC BY-NC-SA altında lisanslanmış açık erişim bir makaledir.
ABSTRACT
To determine the underlying etiologies among hyperprolactinemic cases, evaluate treatment options and patient compliance. Methods: We evaluated the data of 111 hyperporlactinemic patients, admitted to our clinic with hyperprolactinemia from 1999 through 2005 retrospectively. Results: One-hundred-six (95.5%) women, 5 (4.5%) men, mean age of 34.7 ± 11.0 years, were included. Magnetic resonance imaging (MRI) procedures revealed; adenoma in 78 (73.58%) patients; microadenoma in 65 (61.32%), macroadenoma in 13 (12.2%) and normal findings in 28 (26.4%). Microprolactinoma was most prevalent among women (n=68, 64.1%), whereas it was macroprolactinoma among men (n=3, 60%). Higher levels of prolactin were detected in macroadenomas (p<0.05). Cabergoline was the drug of choice for 78.7%, bromocriptine for 28.8 % of cases. Among 82 patients, who were consuming medicine, 57 (69.5%) were on regular follow-up; 23 ± 14 months. Although their tumor size decreased in varying degrees, there was no change among 25 (43.9%) cases, moreover, 10 subjects (17.5%) experienced an increase despite appropriate therapy. Conclusions: Our data was compatible with literature. However, the relatively higher number of cases who were resistant to therapy was a question of debate. We think that in such cases, it is necessary to recheck diagnostic procedures and the patient compliance cautiously.
ÖZET
To determine the underlying etiologies among hyperprolactinemic cases, evaluate treatment options and patient compliance. Methods: We evaluated the data of 111 hyperporlactinemic patients, admitted to our clinic with hyperprolactinemia from 1999 through 2005 retrospectively. Results: One-hundred-six (95.5%) women, 5 (4.5%) men, mean age of 34.7 ± 11.0 years, were included. Magnetic resonance imaging (MRI) procedures revealed; adenoma in 78 (73.58%) patients; microadenoma in 65 (61.32%), macroadenoma in 13 (12.2%) and normal findings in 28 (26.4%). Microprolactinoma was most prevalent among women (n=68, 64.1%), whereas it was macroprolactinoma among men (n=3, 60%). Higher levels of prolactin were detected in macroadenomas (p<0.05). Cabergoline was the drug of choice for 78.7%, bromocriptine for 28.8 % of cases. Among 82 patients, who were consuming medicine, 57 (69.5%) were on regular follow-up; 23 ± 14 months. Although their tumor size decreased in varying degrees, there was no change among 25 (43.9%) cases, moreover, 10 subjects (17.5%) experienced an increase despite appropriate therapy. Conclusions: Our data was compatible with literature. However, the relatively higher number of cases who were resistant to therapy was a question of debate. We think that in such cases, it is necessary to recheck diagnostic procedures and the patient compliance cautiously.